Developer docs
API playgroundTry for free, no card

Search company profiles

Legend Biotech

Full company profile

uuid0000qm6

Namestring
Legend Biotech
Legal namestring
Legend Biotech USA Inc.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Legend Biotech is a global, commercial-stage biopharmaceutical company that develops and commercializes novel cell therapies for oncology. Founded in 2014 and headquartered in Bridgewater, New Jersey, the company operates through subsidiaries across the United States, Europe (Belgium, Ireland), and China (Nanjing), with approximately 3,000 employees worldwide. Legend is a majority-owned affiliate of GenScript Biotech Corporation and is publicly traded on NASDAQ under the ticker LEGN.

The company's core product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed autologous CAR-T cell therapy approved by the FDA in February 2022 and the EMA in May 2022 for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. CARVYKTI is commercialized globally through a 2017 strategic partnership with Johnson & Johnson's Janssen Biotech, with the therapy available at 294 treatment sites across 14 markets and 18 countries, having treated more than 10,000 patients worldwide. Legend operates four proprietary technology platforms — autologous CAR-T, allogeneic non-gene-editing CAR-T, CAR-γδ T, and CAR-NK — and is advancing a pipeline including LB2501 (in vivo CD19/CD20 dual-targeting CAR-T for NHL), LB2102 (DLL3-targeted CAR-T for small cell lung cancer, partnered with Novartis), LB1908 (Claudin 18.2-targeted CAR-T for gastroesophageal cancer), and LUCAR-G39D (allogeneic CD20/CD19 dual-CAR γδ T cells).

Legend Biotech's revenue is generated primarily through collaboration revenue from the Johnson & Johnson partnership for CARVYKTI, with FY2025 collaboration revenue of approximately $1.029 billion (up 64% year-over-year) and Q1 2026 revenue of $305.1 million. CARVYKTI net trade sales (jointly reported with J&J) reached approximately $1.9 billion in FY2025 and $597 million in Q1 2026 (up 62% YoY). Pricing follows the high-cost specialty CAR-T model, typically $400,000–$500,000+ per one-time infusion, with Chinese listings at CNY 999,000–CNY 1.3 million. The company achieves revenue through treatment center distribution rather than direct consumer sales, with manufacturing currently at 10,000 annualized doses and scaling toward 20,000 doses annually. CARVYKTI achieved product-level profitability in 2025 and Legend targets company-wide profitability in 2026.

Short descriptiontext

Legend Biotech is a global commercial-stage biopharmaceutical company developing CAR-T cell therapies for oncology, anchored by FDA-approved CARVYKTI for relapsed/refractory multiple myeloma commercialized with Johnson & Johnson, with a pipeline targeting hematologic malignancies and solid tumors across four proprietary cell therapy platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersSomerset, United States
HQ citystring
Somerset
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CAR-T cell therapy, oncology therapeutics, hematologic malignancies, cell therapy platforms, biopharmaceutical products
Industry4 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy Pharmaceuticals — Oncology Biologics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1CARVYKTI Product Sales
TypeOne Time License
Description

Revenue from global sales of CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T cell therapy for multiple myeloma. Q4 2025 net trade sales of $555 million; full year 2025 net trade sales of approximately $1.9 billion. Revenue grew 64% year-over-year in 2025 to $1.03 billion.

simplywall.st
2Collaboration Revenue from Johnson & Johnson
TypeLicensing Royalties
Description

Legend Biotech shares collaboration revenue with Janssen Biotech (Johnson & Johnson) for the global development and commercialization of CARVYKTI. The partnership involves co-development, cost-sharing, and profit-sharing arrangements.

rootsanalysis.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1CARVYKTI (ciltacabtagene autoleucel) - One-time CAR-T cell therapy for relapsed/refractory multiple myeloma
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Treatment pricing not publicly disclosed; CAR-T therapies are high-cost specialty pharmaceuticals typically priced between $400,000-$500,000+ per infusion. China listed CAR-T therapies including Legend's at CNY 999,000 to CNY 1.3 million per infusion in their first Commercial Health Insurance Innovative Drug List.

legendbiotech.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1CARVYKTI
Description

CAR-T cell therapy product (ciltacabtagene autoleucel) for the treatment of relapsed or refractory multiple myeloma, developed in partnership with Johnson & Johnson

legendbiotech.com
Core offering1 text field

Legend Biotech develops and commercializes novel cell therapies for oncology, with a primary focus on autologous CAR-T cell therapies. Its lead product, CARVYKTI (ciltacabtagene autoleucel), is a BCMA-directed CAR-T therapy approved for the treatment of adult patients with relapsed or refractory multiple myeloma. The company also maintains a pipeline of investigational cell therapies including in vivo CAR-T, DLL3-targeted CAR-T, Claudin 18.2-targeted CAR-T, and allogeneic gamma-delta T cell therapies for hematologic malignancies and solid tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • CARVYKTI achieved 5-year overall survival rates exceeding 85% in CARTITUDE-1 patients
+4 more records
Product overview1 text field

Legend Biotech is a global, commercial-stage biotechnology company and the largest standalone cell therapy company, developing a portfolio of cell therapy products and technology platforms. The company's lead commercial product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for multiple myeloma approved in the US (2022) and EU (2022), marketed in partnership with Johnson & Johnson's Janssen Biotech. Legend Biotech's pipeline includes multiple investigational CAR-T candidates: LB2501 (in vivo CD19/CD20 dual-targeting CAR-T for NHL in Phase 1), LB2102 (DLL3-targeted CAR-T for small cell lung cancer in Phase 1, partnered with Novartis), LB1908 (Claudin 18.2-targeted CAR-T for gastroesophageal cancer in Phase 1), and LUCAR-G39D (allogeneic CD20/CD19 dual-CAR gamma-delta T cells for NHL in Phase 1). The company is built on four technology platforms: autologous CAR-T, CAR-γδ T, CAR-NK, and non-gene-editing universal CAR-T. Legend Biotech operates as an end-to-end cell therapy company with capabilities spanning discovery through commercialization.

Product and service5 records
1CARVYKTI (ciltacabtagene autoleucel)
CategoryCell Therapy — BCMA CAR-T
Description

A BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy administered as a one-time infusion for the treatment of adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy. Developed and commercialized in partnership with Johnson & Johnson's Janssen Biotech.

2LB2501
CategoryPipeline — In Vivo CAR-T
Description

Investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy in Phase 1 development for relapsed or refractory B-cell non-Hodgkin lymphoma. Achieved 100% objective response rate and 83.3% complete response rate at dose level 2 with no dose-limiting toxicities or serious adverse events, and does not require lymphodepletion.

3LB2102
CategoryPipeline — Solid Tumor CAR-T
Description

Investigational DLL3-targeted CAR-T cell therapy armored with dominant-negative TGF-beta receptor 2 (dnTGFBR2) in Phase 1 development for relapsed or refractory small cell lung cancer and large-cell neuroendocrine carcinoma. Demonstrated 28.6% objective response rate and 78.6% disease control rate at higher dose levels. Licensed to Novartis Pharma AG for worldwide development and commercialization (Legend retains US Phase 1 trial).

4LB1908
CategoryPipeline — Solid Tumor CAR-T
Description

Investigational autologous Claudin 18.2-targeted chimeric antigen receptor T-cell product in Phase 1 development for advanced gastroesophageal adenocarcinoma.

5LUCAR-G39D
CategoryPipeline — Allogeneic CAR-T
Description

Novel anti-CD20/CD19 dual-CAR allogeneic gamma-delta T cell therapy in Phase 1 development for relapsed/refractory B-cell non-Hodgkin lymphoma, leveraging the allogeneic CAR-γδ T platform.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-11-01
Description

License agreement for DLL3-targeted CAR-T therapies. Legend Biotech retains responsibility for the ongoing US Phase 1 trial while Novartis holds exclusive worldwide rights for other development, manufacturing, and commercialization of DLL3-targeted CAR-T therapies. LB2102 program is being advanced under this agreement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Strategic collaboration with Janssen Biotech to co-develop and commercialize CARVYKTI (ciltacabtagene autoleucel), Legend's BCMA-directed CAR-T cell therapy for multiple myeloma. Partnership involves global co-development, cost-sharing, and profit-sharing arrangements. J&J leads global commercialization while Legend maintains manufacturing responsibilities in partnership facilities in New Jersey and Belgium.

Strategic tierCoreTypeOthers
Description

GenScript Biotech Corporation is the parent company of Legend Biotech. Legend Biotech Corporation is listed on NASDAQ and operates as an independent entity with GenScript as majority shareholder. Frank Zhang serves as Chairman of Legend Biotech and holds leadership positions at GenScript.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Bristol Myers Squibb
TypeDirect peer
Description

Markets ABECMA (idecabtagene vicleucel), a BCMA-directed CAR-T approved for multiple myeloma — the closest direct competitor to Legend's CARVYKTI in the same indication. BMS is also backing 2seventy bio in patent litigation against Legend.

TypeDirect peer
Description

Discovery and development partner with BMS on ABECMA (BCMA CAR-T for multiple myeloma). Directly competes with Legend in BCMA-directed CAR-T and is the plaintiff in the ongoing CARVYKTI patent dispute at the Unified Patent Court.

TypeBroad incumbent
Description

Markets KYMRIAH, the first FDA-approved CAR-T, and holds exclusive worldwide rights (ex-US Phase 1) to Legend's DLL3 CAR-T LB2102 via a 2023 license agreement. A broad-incumbent cell therapy player and partner/peer along the CAR-T value chain.

TypeDirect peer
Description

Markets YESCARTA and TECARTUS, two approved CAR-T therapies in hematologic malignancies. Kite is a leading CAR-T commercial organization and competes for treatment center capacity and BCMA/BCMA-adjacent patient share.

TypeDirect peer
Description

Commercial-stage cell therapy company with FDA-approved tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Comparable as a focused, commercial-stage cell therapy developer targeting oncology with complex autologous manufacturing.

TypeDirect peer
Description

Clinical-stage allogeneic CAR-T developer. Competes with Legend's allogeneic CAR-γδ T and non-gene-editing universal CAR-T programs in the off-the-shelf CAR-T space.

TypeEmerging player
Description

Developer of cell therapies for solid tumors, including TCR-T cell therapies with comparable patient target populations (e.g., DLL3 in SCLC). Comparable as a cell therapy developer focused on intractable solid tumor indications.

TypeEmerging player
Description

Clinical-stage allogeneic CAR-T developer using CRISPR gene editing. Comparable as an emerging allogeneic CAR-T competitor overlapping with Legend's non-gene-editing universal CAR-T platform.

TypeEmerging player
Description

Gene-edited cell therapy developer (CASGEVY for sickle cell disease, allogeneic CAR-T programs). Comparable as a cell/gene therapy developer pushing novel modalities including gene editing.

TypeEmerging player
Description

iPSC-derived off-the-shelf NK and T-cell therapy developer. Comparable as an emerging player in the allogeneic cell therapy space with overlapping CAR-NK and engineered T-cell modalities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Legend Biotech

Cell Therapy Pharmaceuticals — Oncology Biologicslegendbiotech.com

Legend Biotech is a global commercial-stage biopharmaceutical company developing CAR-T cell therapies for oncology, anchored by FDA-approved CARVYKTI for relapsed/refractory multiple myeloma commercialized with Johnson & Johnson, with a pipeline targeting hematologic malignancies and solid tumors across four proprietary cell therapy platforms.

What Legend Biotech does

Legend Biotech is a global, commercial-stage biopharmaceutical company that develops and commercializes novel cell therapies for oncology. Founded in 2014 and headquartered in Bridgewater, New Jersey, the company operates through subsidiaries across the United States, Europe (Belgium, Ireland), and China (Nanjing), with approximately 3,000 employees worldwide. Legend is a majority-owned affiliate of GenScript Biotech Corporation and is publicly traded on NASDAQ under the ticker LEGN.

The company's core product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed autologous CAR-T cell therapy approved by the FDA in February 2022 and the EMA in May 2022 for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. CARVYKTI is commercialized globally through a 2017 strategic partnership with Johnson & Johnson's Janssen Biotech, with the therapy available at 294 treatment sites across 14 markets and 18 countries, having treated more than 10,000 patients worldwide. Legend operates four proprietary technology platforms — autologous CAR-T, allogeneic non-gene-editing CAR-T, CAR-γδ T, and CAR-NK — and is advancing a pipeline including LB2501 (in vivo CD19/CD20 dual-targeting CAR-T for NHL), LB2102 (DLL3-targeted CAR-T for small cell lung cancer, partnered with Novartis), LB1908 (Claudin 18.2-targeted CAR-T for gastroesophageal cancer), and LUCAR-G39D (allogeneic CD20/CD19 dual-CAR γδ T cells).

Legend Biotech's revenue is generated primarily through collaboration revenue from the Johnson & Johnson partnership for CARVYKTI, with FY2025 collaboration revenue of approximately $1.029 billion (up 64% year-over-year) and Q1 2026 revenue of $305.1 million. CARVYKTI net trade sales (jointly reported with J&J) reached approximately $1.9 billion in FY2025 and $597 million in Q1 2026 (up 62% YoY). Pricing follows the high-cost specialty CAR-T model, typically $400,000–$500,000+ per one-time infusion, with Chinese listings at CNY 999,000–CNY 1.3 million. The company achieves revenue through treatment center distribution rather than direct consumer sales, with manufacturing currently at 10,000 annualized doses and scaling toward 20,000 doses annually. CARVYKTI achieved product-level profitability in 2025 and Legend targets company-wide profitability in 2026.

Legend Biotech firmographics

Firmographics
Name
Legend Biotech
Legal name
Legend Biotech USA Inc.
Website
https://legendbiotech.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Legend Biotech is a global commercial-stage biopharmaceutical company developing CAR-T cell therapies for oncology, anchored by FDA-approved CARVYKTI for relapsed/refractory multiple myeloma commercialized with Johnson & Johnson, with a pipeline targeting hematologic malignancies and solid tumors across four proprietary cell therapy platforms.
Ownership category
akta.pro rank

Legend Biotech industry classification

Industry
Product category
Cell Therapy Pharmaceuticals — Oncology Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • CAR-T cell therapy
  • Oncology therapeutics
  • Hematologic malignancies
  • Cell therapy platforms
  • Biopharmaceutical products

Where Legend Biotech is headquartered

Location

Headquarters

HQ city
Somerset
HQ country
United States
HQ region
North America

Offices7 records

Markets served

Legend Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. CARVYKTI Product Sales: Revenue from global sales of CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T cell therapy for multiple myeloma. Q4 2025 net trade sales of $555 million; full year 2025 net trade sales of approximately $1.9 billion. Revenue grew 64% year-over-year in 2025 to $1.03 billion.
  2. Collaboration Revenue from Johnson & Johnson: Legend Biotech shares collaboration revenue with Janssen Biotech (Johnson & Johnson) for the global development and commercialization of CARVYKTI. The partnership involves co-development, cost-sharing, and profit-sharing arrangements.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goCARVYKTI (ciltacabtagene autoleucel) - One-time CAR-T cell therapy for relapsed/refractory multiple myeloma

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Legend Biotech product offering

Product offering

Core offering

Legend Biotech develops and commercializes novel cell therapies for oncology, with a primary focus on autologous CAR-T cell therapies. Its lead product, CARVYKTI (ciltacabtagene autoleucel), is a BCMA-directed CAR-T therapy approved for the treatment of adult patients with relapsed or refractory multiple myeloma. The company also maintains a pipeline of investigational cell therapies including in vivo CAR-T, DLL3-targeted CAR-T, Claudin 18.2-targeted CAR-T, and allogeneic gamma-delta T cell therapies for hematologic malignancies and solid tumors.

Product overview

Legend Biotech is a global, commercial-stage biotechnology company and the largest standalone cell therapy company, developing a portfolio of cell therapy products and technology platforms. The company's lead commercial product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for multiple myeloma approved in the US (2022) and EU (2022), marketed in partnership with Johnson & Johnson's Janssen Biotech. Legend Biotech's pipeline includes multiple investigational CAR-T candidates: LB2501 (in vivo CD19/CD20 dual-targeting CAR-T for NHL in Phase 1), LB2102 (DLL3-targeted CAR-T for small cell lung cancer in Phase 1, partnered with Novartis), LB1908 (Claudin 18.2-targeted CAR-T for gastroesophageal cancer in Phase 1), and LUCAR-G39D (allogeneic CD20/CD19 dual-CAR gamma-delta T cells for NHL in Phase 1). The company is built on four technology platforms: autologous CAR-T, CAR-γδ T, CAR-NK, and non-gene-editing universal CAR-T. Legend Biotech operates as an end-to-end cell therapy company with capabilities spanning discovery through commercialization.

Differentiator

Problem solved

Functional benefit

Brands

  • CARVYKTI: CAR-T cell therapy product (ciltacabtagene autoleucel) for the treatment of relapsed or refractory multiple myeloma, developed in partnership with Johnson & Johnson

Products and services

  • CARVYKTI (ciltacabtagene autoleucel) A BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy administered as a one-time infusion for the treatment of adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy. Developed and commercialized in partnership with Johnson & Johnson's Janssen Biotech.
  • LB2501 Investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy in Phase 1 development for relapsed or refractory B-cell non-Hodgkin lymphoma. Achieved 100% objective response rate and 83.3% complete response rate at dose level 2 with no dose-limiting toxicities or serious adverse events, and does not require lymphodepletion.
  • LB2102 Investigational DLL3-targeted CAR-T cell therapy armored with dominant-negative TGF-beta receptor 2 (dnTGFBR2) in Phase 1 development for relapsed or refractory small cell lung cancer and large-cell neuroendocrine carcinoma. Demonstrated 28.6% objective response rate and 78.6% disease control rate at higher dose levels. Licensed to Novartis Pharma AG for worldwide development and commercialization (Legend retains US Phase 1 trial).
  • LB1908 Investigational autologous Claudin 18.2-targeted chimeric antigen receptor T-cell product in Phase 1 development for advanced gastroesophageal adenocarcinoma.
  • LUCAR-G39D Novel anti-CD20/CD19 dual-CAR allogeneic gamma-delta T cell therapy in Phase 1 development for relapsed/refractory B-cell non-Hodgkin lymphoma, leveraging the allogeneic CAR-γδ T platform.

Quantifiable outcome

  • CARVYKTI achieved 5-year overall survival rates exceeding 85% in CARTITUDE-1 patients
  • +4 more outcomes

Companies that use Legend Biotech

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Legend Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Legend Biotech partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major and core.

  • Novartis Pharma AGmajorOEM/ Whitelabel/ Licensing Partner · 1 November 2023License agreement for DLL3-targeted CAR-T therapies. Legend Biotech retains responsibility for the ongoing US Phase 1 trial while Novartis holds exclusive worldwide rights for other development, manufacturing, and commercialization of DLL3-targeted CAR-T therapies. LB2102 program is being advanced under this agreement.
  • Johnson & Johnson (Janssen Biotech)coreStrategic or Co-development Partner · 1 January 2017Strategic collaboration with Janssen Biotech to co-develop and commercialize CARVYKTI (ciltacabtagene autoleucel), Legend's BCMA-directed CAR-T cell therapy for multiple myeloma. Partnership involves global co-development, cost-sharing, and profit-sharing arrangements. J&J leads global commercialization while Legend maintains manufacturing responsibilities in partnership facilities in New Jersey and Belgium.
  • GenScript Biotech CorporationcoreOthersGenScript Biotech Corporation is the parent company of Legend Biotech. Legend Biotech Corporation is listed on NASDAQ and operates as an independent entity with GenScript as majority shareholder. Frank Zhang serves as Chairman of Legend Biotech and holds leadership positions at GenScript.

Scale indicators15 records

Recent moves11 records

Expansion highlights5 records

Legend Biotech competitors and assessment

Company assessment

Direct peers

  • Bristol Myers Squibb: Markets ABECMA (idecabtagene vicleucel), a BCMA-directed CAR-T approved for multiple myeloma — the closest direct competitor to Legend's CARVYKTI in the same indication. BMS is also backing 2seventy bio in patent litigation against Legend.
  • 2seventy bio: Discovery and development partner with BMS on ABECMA (BCMA CAR-T for multiple myeloma). Directly competes with Legend in BCMA-directed CAR-T and is the plaintiff in the ongoing CARVYKTI patent dispute at the Unified Patent Court.
  • Kite Pharma (Gilead Sciences): Markets YESCARTA and TECARTUS, two approved CAR-T therapies in hematologic malignancies. Kite is a leading CAR-T commercial organization and competes for treatment center capacity and BCMA/BCMA-adjacent patient share.
  • Iovance Biotherapeutics: Commercial-stage cell therapy company with FDA-approved tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Comparable as a focused, commercial-stage cell therapy developer targeting oncology with complex autologous manufacturing.
  • Allogene Therapeutics: Clinical-stage allogeneic CAR-T developer. Competes with Legend's allogeneic CAR-γδ T and non-gene-editing universal CAR-T programs in the off-the-shelf CAR-T space.

Broad incumbents

  • Novartis: Markets KYMRIAH, the first FDA-approved CAR-T, and holds exclusive worldwide rights (ex-US Phase 1) to Legend's DLL3 CAR-T LB2102 via a 2023 license agreement. A broad-incumbent cell therapy player and partner/peer along the CAR-T value chain.

Emerging players

  • Adaptimmune Therapeutics: Developer of cell therapies for solid tumors, including TCR-T cell therapies with comparable patient target populations (e.g., DLL3 in SCLC). Comparable as a cell therapy developer focused on intractable solid tumor indications.
  • Caribou Biosciences: Clinical-stage allogeneic CAR-T developer using CRISPR gene editing. Comparable as an emerging allogeneic CAR-T competitor overlapping with Legend's non-gene-editing universal CAR-T platform.
  • CRISPR Therapeutics: Gene-edited cell therapy developer (CASGEVY for sickle cell disease, allogeneic CAR-T programs). Comparable as a cell/gene therapy developer pushing novel modalities including gene editing.
  • Fate Therapeutics: iPSC-derived off-the-shelf NK and T-cell therapy developer. Comparable as an emerging player in the allogeneic cell therapy space with overlapping CAR-NK and engineered T-cell modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Legend Biotech social profiles

Digital presence

Legend Biotech compliance and trust

Trust signal

Compliance1 record

Legend Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Legend Biotech leadership team

Management profile

Number of profiles

Profiles15 records

Legend Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

Legend Biotech funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Legend Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Legend Biotech

What does Legend Biotech do?

Legend Biotech develops and commercializes novel cell therapies for oncology, with a primary focus on autologous CAR-T cell therapies. Its lead product, CARVYKTI (ciltacabtagene autoleucel), is a BCMA-directed CAR-T therapy approved for the treatment of adult patients with relapsed or refractory multiple myeloma. The company also maintains a pipeline of investigational cell therapies including in vivo CAR-T, DLL3-targeted CAR-T, Claudin 18.2-targeted CAR-T, and allogeneic gamma-delta T cell therapies for hematologic malignancies and solid tumors.

Is Legend Biotech a public or private company?

Legend Biotech is a public company. It is classified as public and is currently operating.

When was Legend Biotech founded?

Legend Biotech was founded in 2014. It employs 1,001 to 5,000 people.

Where is Legend Biotech based?

Legend Biotech is headquartered in Somerset, United States, in the North America region.

How does Legend Biotech make money?

Two revenue lines are on record. CARVYKTI Product Sales are the primary driver. The others are collaboration Revenue from Johnson & Johnson.

Who are Legend Biotech's main competitors?

Direct peers on record are Bristol Myers Squibb, 2seventy bio, Kite Pharma (Gilead Sciences), Iovance Biotherapeutics and Allogene Therapeutics. Novartis is listed as a broad incumbent. Emerging players are Adaptimmune Therapeutics, Caribou Biosciences, CRISPR Therapeutics and Fate Therapeutics.

Does Legend Biotech have an API?

No public API is recorded for Legend Biotech.

What industry is Legend Biotech in?

Legend Biotech's product category is Cell Therapy Pharmaceuticals — Oncology Biologics. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewEvercore ISI Group downgrades Legend Biotech to In-Line from Outperform, sets price target at $20Evercore ISI Group downgraded Legend Biotech to In-Line from Outperform and set a price target of $20. The target implies a 14.3% upside from the Nov 13 close of $17.50. Recent analyst price targets range from $25 to $61.Seeking AlphaLegend Biotech Corporation 2026 Q3 - Results - Earnings Call PresentationLegend Biotech reported Q3 2026 EPS of $0.28, beating by $0.27, but revenue of $359.50M missed by $411.56K. Revenue growth of 32.01% year-over-year was also reported.Simply Wall StLegend Biotech Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsLegend Biotech reported statutory EPS of US$0.26, crushing expectations, while revenue of US$360m was near consensus. Analysts cut their 2027 revenue forecast to US$1.70b and price targets to US$42.46, though earnings forecasts remained unchanged.Defense WorldBarclays Has Lowered Expectations for Legend Biotech (NASDAQ:LEGN) Stock PriceBarclays lowered its price target for Legend Biotech to $61 from $68, keeping an overweight rating. The company reported Q3 EPS of $0.14, beating estimates, with revenue of $359.5 million, up 32% year over year. Analysts have a consensus "Moderate Buy" rating with a $50.85 price target.Defense WorldRoyal Bank Of Canada Issues Pessimistic Forecast for Legend Biotech (NASDAQ:LEGN) Stock PriceRoyal Bank of Canada lowered its Legend Biotech price target to $50 from $56, keeping an outperform rating. The stock opened at $18.54, and Q3 EPS of $0.14 beat the $0.01 consensus, though revenue of $359.5M fell short of estimates.American Banking and Market NewsLegend Biotech Corporation Sponsored ADR $LEGN Stock: IvyRock Asset Management HK Ltd Decreases StakeIvyRock Asset Management HK Ltd reduced its Legend Biotech stake by 3.8% in Q3, selling 30,800 shares. Legend Biotech reported Q3 EPS of $0.14, beating estimates, with revenue of $359.5 million, up 32% year over year. Analysts have a consensus price target of $50.85.TradingViewMorgan Stanley maintains Legend Biotech at Overweight, lowers price target to $43 from $49Morgan Stanley maintained Legend Biotech at Overweight and lowered its price target to $43 from $49, a 12.2% decrease. The target implies an upside of 110.7% from the Nov 10 close of $20.41.TradingViewBarclays maintains Legend Biotech at Overweight, lowers price target to $61 from $68Barclays maintained Legend Biotech at Overweight and lowered its price target to $61 from $68, a 10.3% decrease. The target implies an upside of 198.9% from the Nov 10 close of $20.41.TradingViewRBC Capital maintains Legend Biotech at Outperform, lowers price target to $50 from $56RBC Capital maintained Legend Biotech at Outperform and lowered its price target to $50 from $56, a 10.7% decrease. The target implies 145% upside from the Nov 10 close of $20.41.FiercePharmaLegend Biotech shares fall 16% after first earnings report under new CEOLegend Biotech shares fell 16% after its Q3 earnings report, with adjusted net income of $56 million, down from $63 million in Q2. CFO Carlos Santos said Wall Street's 2027 sales consensus is higher than anticipated, citing slower U.S. earlier-line share growth. CEO Ingrid Zhang aims to overcome rollout hurdles to support Carvykti's $5 billion peak sales estimate.